Biological Products, (No Diagnostic Substances) Companies
FilingsAtlas covers 135 publicly traded US companies in the Biological Products, (No Diagnostic Substances) industry (SEC SIC code 2836). Together they are worth about $772.49B in market value; the largest are Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA). By revenue, the biggest is Amgen with $36.75B in fiscal 2025. 20 of the 135 companies with a reported fiscal year were profitable.
| # | Company | Ticker | Market Cap | Revenue (latest FY) | Net Income | Revenue YoY | P/E |
|---|---|---|---|---|---|---|---|
| 1 | Amgen Inc | AMGN | $224.58B | $36.75B FY2025 | $7.71B | +10.0% | 29.0 |
| 2 | Gilead Sciences, Inc. | GILD | $183.86B | $29.44B FY2025 | $8.51B | +2.4% | 21.8 |
| 3 | Moderna, Inc. | MRNA | $86.07B | $1.94B FY2025 | -$2.82B | -39.9% | — |
| 4 | Revolution Medicines, Inc. | RVMD | $39.74B | $0 FY2025 | -$1.13B | — | — |
| 5 | Biogen Inc. | BIIB | $34.04B | $9.89B FY2025 | $1.29B | +2.2% | 26.0 |
| 6 | Exelixis, Inc. | EXEL | $15.45B | $2.32B FY2025 | $782.6M | +7.0% | 21.4 |
| 7 | Neurocrine Biosciences Inc | NBIX | $14.08B | $2.86B FY2025 | $478.6M | +21.4% | 28.9 |
| 8 | Halozyme Therapeutics, Inc. | HALO | $13.29B | $1.40B FY2025 | $316.9M | +37.5% | 42.8 |
| 9 | BIO-TECHNE Corp | TECH | $11.38B | $1.22B FY2026 | $181.9M | -0.4% | 62.5 |
| 10 | Kymera Therapeutics, Inc. | KYMR | $10.47B | $39.2M FY2025 | -$311.4M | -16.7% | — |
| 11 | ImmunityBio, Inc. | IBRX | $10.29B | $113.3M FY2025 | -$351.4M | +668.3% | — |
| 12 | Repligen Corp | RGEN | $9.94B | $738.3M FY2025 | $48.9M | +16.4% | 204.0 |
| 13 | Krystal Biotech, Inc. | KRYS | $9.85B | $389.1M FY2025 | $204.8M | +33.9% | 47.0 |
| 14 | Vaxcyte, Inc. | PCVX | $9.65B | $0 FY2025 | -$766.6M | — | — |
| 15 | Twist Bioscience Corp | TWST | $9.44B | $376.6M FY2025 | -$77.7M | +20.3% | — |
| 16 | Iovance Biotherapeutics, Inc. | IOVA | $6.53B | $263.5M FY2025 | -$391.0M | +60.6% | — |
| 17 | Immunovant, Inc. | IMVT | $5.90B | $0 FY2026 | -$505.6M | — | — |
| 18 | Kodiak Sciences Inc. | KOD | $5.74B | $0 FY2025 | -$230.0M | — | — |
| 19 | CG Oncology, Inc. | CGON | $5.50B | $4.0M FY2025 | -$161.0M | +254.7% | — |
| 20 | Scholar Rock Holding Corp | SRRK | $5.29B | $0 FY2025 | -$377.9M | — | — |
| 21 | CRISPR Therapeutics AG | CRSP | $4.84B | $3.5M FY2025 | -$581.6M | -90.6% | — |
| 22 | Adaptive Biotechnologies Corp | ADPT | $4.04B | $277.0M FY2025 | -$59.5M | +54.8% | — |
| 23 | Relay Therapeutics, Inc. | RLAY | $3.52B | $15.4M FY2025 | -$276.5M | +53.4% | — |
| 24 | Denali Therapeutics Inc. | DNLI | $3.45B | $0 FY2025 | -$512.5M | — | — |
| 25 | Tarsus Pharmaceuticals, Inc. | TARS | $3.07B | $451.4M FY2025 | -$66.4M | +146.7% | — |
| 26 | Beam Therapeutics Inc. | BEAM | $2.55B | $139.7M FY2025 | -$80.0M | +120.0% | — |
| 27 | Adma Biologics, Inc. | ADMA | $2.37B | $510.2M FY2025 | $146.9M | +19.6% | 17.2 |
| 28 | Biocryst Pharmaceuticals Inc | BCRX | $2.14B | $874.8M FY2025 | $263.9M | +94.1% | 6.7 |
| 29 | Novavax Inc | NVAX | $2.11B | $1.12B FY2025 | $440.3M | +64.7% | 5.0 |
| 30 | Vericel Corp | VCEL | $2.11B | $276.3M FY2025 | $16.5M | +16.4% | 125.9 |
| 31 | Recursion Pharmaceuticals, Inc. | RXRX | $2.04B | $74.7M FY2025 | -$644.8M | +26.9% | — |
| 32 | Vir Biotechnology, Inc. | VIR | $1.79B | $68.6M FY2025 | -$438.0M | -7.6% | — |
| 33 | Maze Therapeutics, Inc. | MAZE | $1.57B | $0 FY2025 | -$131.1M | — | — |
| 34 | Immunocore Holdings plc | IMCR | $1.42B | $400.0M FY2025 | -$35.5M | +28.9% | — |
| 35 | Inhibrx Biosciences, Inc. | INBX | $1.36B | $1.3M FY2025 | -$140.1M | +550.0% | — |
| 36 | Taysha Gene Therapies, Inc. | TSHA | $1.32B | $9.8M FY2025 | -$109.0M | +17.3% | — |
| 37 | Replimune Group, Inc. | REPL | $1.17B | $0 FY2026 | -$313.9M | — | — |
| 38 | Vor Biopharma Inc. | VOR | $1.04B | $0 FY2025 | -$696.0M | — | — |
| 39 | Monte Rosa Therapeutics, Inc. | GLUE | $1.00B | $123.7M FY2025 | -$38.6M | +63.5% | — |
| 40 | MeiraGTx Holdings plc | MGTX | $932.4M | $81.4M FY2025 | -$114.2M | +144.6% | — |
| 41 | 4D Molecular Therapeutics, Inc. | FDMT | $868.6M | $85.2M FY2025 | -$140.1M | — | — |
| 42 | Solid Biosciences Inc. | SLDB | $836.3M | $0 FY2025 | -$174.3M | — | — |
| 43 | DBV Technologies S.A. | DBVT | $783.0M | $5.6M FY2025 | -$146.9M | +35.8% | — |
| 44 | Ginkgo Bioworks Holdings, Inc. | DNA | $730.2M | $170.2M FY2025 | -$312.8M | -25.1% | — |
| 45 | Sana Biotechnology, Inc. | SANA | $712.6M | $0 FY2025 | -$244.2M | — | — |
| 46 | Candel Therapeutics, Inc. | CADL | $687.2M | $0 FY2025 | -$38.2M | — | — |
| 47 | Aura Biosciences, Inc. | AURA | $594.8M | $0 FY2025 | -$106.2M | — | — |
| 48 | Prime Medicine, Inc. | PRME | $588.4M | $4.6M FY2025 | -$201.1M | +55.3% | — |
| 49 | Zura Bio Ltd | ZURA | $536.4M | $0 FY2025 | -$68.7M | — | — |
| 50 | Autolus Therapeutics plc | AUTL | $431.2M | $75.4M FY2025 | -$287.5M | +644.9% | — |
| 51 | Allogene Therapeutics, Inc. | ALLO | $424.3M | $0 FY2025 | -$190.9M | -100.0% | — |
| 52 | Tectonic Therapeutic, Inc. | TECX | $404.1M | $0 FY2025 | -$74.2M | — | — |
| 53 | REGENXBIO Inc. | RGNX | $384.9M | $170.4M FY2025 | -$193.9M | +104.5% | — |
| 54 | Fennec Pharmaceuticals Inc. | FENC | $370.9M | $44.6M FY2025 | -$9.7M | -6.1% | — |
| 55 | C4 Therapeutics, Inc. | CCCC | $363.3M | $35.9M FY2025 | -$105.0M | +1.0% | — |
| 56 | Kyverna Therapeutics, Inc. | KYTX | $351.4M | $0 FY2025 | -$161.3M | — | — |
| 57 | X4 Pharmaceuticals, Inc | XFOR | $328.5M | $6.5M FY2025 | -$79.2M | +154.2% | — |
| 58 | Palisade Bio, Inc. | PALI | $310.7M | $0 FY2025 | -$16.8M | — | — |
| 59 | Inhibikase Therapeutics, Inc. | IKT | $307.2M | $0 FY2025 | -$48.3M | — | — |
| 60 | Ocugen, Inc. | OCGN | $299.7M | $4.4M FY2025 | -$67.8M | +8.8% | — |
| 61 | Prokidney Corp. | PROK | $292.9M | $893,000 FY2025 | -$69.0M | — | — |
| 62 | Editas Medicine, Inc. | EDIT | $291.7M | $40.5M FY2025 | -$160.1M | +25.4% | — |
| 63 | Agenus Inc | AGEN | $287.3M | $114.2M FY2025 | $115,000 | +10.4% | — |
| 64 | Century Therapeutics, Inc. | IPSC | $284.0M | $109.2M FY2025 | -$9.6M | — | — |
| 65 | Cabaletta Bio, Inc. | CABA | $255.5M | $0 FY2025 | -$167.9M | — | — |
| 66 | Artiva Biotherapeutics, Inc. | ARTV | $247.9M | $0 FY2025 | -$83.9M | -100.0% | — |
| 67 | Fate Therapeutics Inc | FATE | $240.8M | $6.6M FY2025 | -$136.3M | -51.2% | — |
| 68 | Lineage Cell Therapeutics, Inc. | LCTX | $237.9M | $14.6M FY2025 | -$63.5M | +53.2% | — |
| 69 | Lexeo Therapeutics, Inc. | LXEO | $234.6M | $0 FY2025 | -$100.0M | — | — |
| 70 | Protalix BioTherapeutics, Inc. | PLX | $227.0M | $52.7M FY2025 | -$6.6M | -1.2% | — |
| 71 | SAB Biotherapeutics, Inc. | SABS | $213.7M | $0 FY2025 | $13.3M | -100.0% | — |
| 72 | Alector, Inc. | ALEC | $208.0M | $21.0M FY2025 | -$142.9M | -79.1% | — |
| 73 | Invivyd, Inc. | IVVD | $207.0M | $53.4M FY2025 | -$52.5M | +110.5% | — |
| 74 | Armata Pharmaceuticals, Inc. | ARMP | $192.3M | $0 FY2025 | -$173.8M | — | — |
| 75 | Alpha Cognition Inc. | ACOG | $191.6M | $10.2M FY2025 | -$20.7M | — | — |
| 76 | Sutro Biopharma, Inc. | STRO | $182.5M | $102.5M FY2025 | -$191.1M | +65.2% | — |
| 77 | Quince Therapeutics, Inc. | QNCX | $170.9M | $0 FY2025 | -$84.0M | — | — |
| 78 | Coherus Oncology, Inc. | CHRS | $165.7M | $42.2M FY2025 | $168.0M | -84.2% | 0.7 |
| 79 | Compass Therapeutics, Inc. | CMPX | $160.1M | $0 FY2025 | -$66.5M | -100.0% | — |
| 80 | Protara Therapeutics, Inc. | TARA | $159.8M | $0 FY2025 | -$57.4M | — | — |
| 81 | Precision Biosciences Inc | DTIL | $157.7M | $34.3M FY2025 | -$45.7M | -50.1% | — |
| 82 | Athira Pharma, Inc. | ATHA | $152.6M | $0 FY2025 | -$105.6M | — | — |
| 83 | Atara Biotherapeutics, Inc. | ATRA | $139.9M | $120.8M FY2025 | $32.7M | -6.3% | 3.6 |
| 84 | Anavex Life Sciences Corp. | AVXL | $137.5M | $0 FY2025 | -$46.4M | — | — |
| 85 | Acumen Pharmaceuticals, Inc. | ABOS | $131.1M | $0 FY2025 | -$121.3M | — | — |
| 86 | Voyager Therapeutics, Inc. | VYGR | $130.2M | $40.4M FY2025 | -$119.7M | -49.5% | — |
| 87 | Entera Bio Ltd. | ENTX | $125.6M | $42,000 FY2025 | -$11.4M | -76.8% | 10.0 |
| 88 | enGene Holdings Inc. | ENGN | $113.7M | $0 FY2025 | -$117.3M | — | 0.7 |
| 89 | Tenaya Therapeutics, Inc. | TNYA | $113.4M | $0 FY2025 | -$90.6M | — | — |
| 90 | LENZ Therapeutics, Inc. | LENZ | $106.7M | $19.1M FY2025 | -$82.1M | — | — |
| 91 | Black Diamond Therapeutics, Inc. | BDTX | $96.4M | $70.0M FY2025 | $22.4M | — | 4.3 |
| 92 | Eloxx Pharmaceuticals, Inc. | ELOX | $86.2M | $0 FY2025 | -$6.0M | — | — |
| 93 | Humacyte, Inc. | HUMA | $84.1M | $2.0M FY2025 | -$40.8M | — | — |
| 94 | Outlook Therapeutics, Inc. | OTLK | $77.1M | $1.4M FY2025 | -$62.4M | — | — |
| 95 | Cognition Therapeutics Inc | CGTX | $72.7M | $0 FY2025 | -$23.5M | — | — |
| 96 | Pelthos Therapeutics Inc. | PTHS | $71.8M | $16.8M FY2025 | -$43.3M | — | — |
| 97 | Cardiff Oncology, Inc. | CRDF | $69.1M | $593,000 FY2025 | -$45.9M | -13.2% | — |
| 98 | Ikena Oncology, Inc. | IKNA | $68.5M | $800,000 FY2025 | -$45.3M | — | — |
| 99 | Neumora Therapeutics, Inc. | NMRA | $68.5M | $0 FY2025 | -$236.9M | — | — |
| 100 | Champions Oncology, Inc. | CSBR | $68.1M | $59.4M FY2026 | -$1.2M | +4.4% | — |
| 101 | Aligos Therapeutics, Inc. | ALGS | $57.5M | $2.2M FY2025 | -$24.2M | -39.5% | — |
| 102 | Kalaris Therapeutics, Inc. | KLRS | $53.1M | $0 FY2025 | -$43.4M | — | — |
| 103 | MiNK Therapeutics, Inc. | INKT | $51.4M | $0 FY2025 | -$12.5M | — | — |
| 104 | Caribou Biosciences, Inc. | CRBU | $47.5M | $11.2M FY2025 | -$148.1M | +11.7% | — |
| 105 | Inmune Bio, Inc. | INMB | $44.9M | $50,000 FY2025 | -$45.9M | +257.1% | — |
| 106 | Instil Bio, Inc. | TIL | $41.9M | $9.0M FY2025 | -$71.4M | +110.2% | — |
| 107 | Exozymes Inc. | EXOZ | $39.8M | — FY2025 | -$9.2M | — | — |
| 108 | Metagenomi, Inc. | MGX | $34.5M | $25.2M FY2025 | -$87.9M | -51.8% | — |
| 109 | Elutia Inc. | ELUT | $34.2M | $12.3M FY2025 | $53.4M | -49.6% | 0.9 |
| 110 | TScan Therapeutics, Inc. | TCRX | $28.2M | $10.3M FY2025 | -$129.8M | +266.7% | — |
| 111 | Tevogen Bio Holdings Inc. | TVGN | $27.2M | $0 FY2025 | -$26.3M | — | — |
| 112 | Black Hawk Acquisition Corp | BKHA | $26.5M | $0 FY2025 | $1.3M | — | — |
| 113 | In8bio, Inc. | INAB | $23.0M | $0 FY2025 | -$19.4M | — | — |
| 114 | Cel Sci Corp | CVM | $21.2M | $0 FY2025 | -$25.4M | — | — |
| 115 | Scilex Holding Co | SCLX | $19.8M | $30.3M FY2025 | -$374.1M | -46.5% | — |
| 116 | aTYR PHARMA INC | ATYR | $19.7M | $190,000 FY2025 | -$74.1M | -19.1% | — |
| 117 | Dyadic International Inc | DYAI | $15.7M | $3.1M FY2025 | -$7.4M | -11.6% | — |
| 118 | Jasper Therapeutics, Inc. | JSPR | $14.2M | $42.2M FY2025 | -$75.8M | — | — |
| 119 | Klotho Neurosciences, Inc. | KLTO | $14.0M | $0 FY2025 | -$10.6M | — | — |
| 120 | Estrella Immunopharma, Inc. | ESLA | $13.5M | $0 FY2025 | -$13.1M | — | — |
| 121 | BioCardia, Inc. | BCDA | $12.0M | $0 FY2025 | -$8.2M | -100.0% | — |
| 122 | Passage BIO, Inc. | PASG | $11.7M | $0 FY2025 | -$45.5M | — | — |
| 123 | Intensity Therapeutics, Inc. | INTS | $9.6M | $0 FY2025 | -$11.6M | — | — |
| 124 | Pluri Inc. | PLUR | $9.2M | $1.0M FY2026 | -$23.8M | -23.9% | — |
| 125 | Senti Biosciences, Inc. | SNTI | $7.9M | $22,000 FY2025 | -$61.4M | — | — |
| 126 | PharmaCyte Biotech, Inc. | PMCB | $3.8M | $0 FY2026 | -$19.4M | — | — |
| 127 | Liminatus Pharma, Inc. | LIMN | $3.3M | $0 FY2025 | -$10.2M | — | — |
| 128 | Creative Medical Technology Holdings, Inc. | CELZ | $3.0M | $6,000 FY2025 | -$6.0M | -45.5% | — |
| 129 | AIM ImmunoTech Inc. | AIM | $2.9M | $88,000 FY2025 | -$14.0M | -48.2% | — |
| 130 | Curis Inc | CRIS | $1.3M | $9.4M FY2025 | -$7.6M | -13.4% | — |
| 131 | Calidi Biotherapeutics, Inc. | CLDI | $1.3M | $0 FY2025 | -$19.9M | — | — |
| 132 | VivoSim Labs, INC. | VIVS | $890,709 | $131,000 FY2026 | -$13.8M | -9.0% | — |
| 133 | Surrozen, Inc. | SRZN | $544,162 | $3.5M FY2025 | -$242.0M | -67.4% | — |
| 134 | Silexion Therapeutics Corp | SLXN | $120,974 | $155,000 FY2025 | -$11.9M | +453.6% | 0.0 |
| 135 | Cullinan Therapeutics, Inc. | CGEM | — | $0 FY2025 | -$219.9M | — | — |
Market cap and P/E use the latest closing price; revenue and net income are from each company's most recent annual report (10-K) filed with the SEC. Click a company for its full financial statements.